Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report third quarter 2025 financial results on Wednesday, November 12, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Investors must register in advance to receive dial-in numbers and PIN; the live webcast link will be provided and an archived webcast will be available for at least 30 days in the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ABOS gained 4.64%, reflecting a moderate positive market reaction. This price movement added approximately $6M to the company's valuation, bringing the market cap to $126M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) report Q3 2025 results?
What time is the Acumen (ABOS) Q3 2025 earnings call and webcast?
How do I join the Acumen (ABOS) November 12, 2025 conference call?
Will Acumen (ABOS) provide a replay of the November 12, 2025 webcast?
Where can investors find the Acumen (ABOS) webcast link and archive?
